Additional work will clarify if these two groups were derived from tumours or patients with distinct biological traits, in particular to confirm a prevalence of stage I tumours from heavy smokers or CTNNB1-mutated tumours to give rise to sgADC or a slightly higher tendency of KRAS-mutated tumours to give rise to fgADC. The gene discussed is KRAS; the disease is neoplasm.